Platelet Function Patents: Who Leads, Where the Gaps Are 2026
- 40.0% concentration. The top five assignees account for 146 of 365 records in scope, a level of concentration that narrows where a new entrant can file without crossing established claims.
- Growth resumed, not steady. Filings ran 16 in 2017 up to a peak of 33 in 2018, then filings climbed again from 7 in 2021 to 11 in 2024, a +57% rise over that span.
- Assay classes trail therapy classes. G01N material analysis and testing appears on 29.3% of records versus 67.9% for medicinal preparations, showing assay-method claims are far less crowded than drug-composition claims.
Filing growth compares 2021 (7 records) with 2024 (11) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 365 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks patent activity at the intersection of platelet function testing and antiplatelet drug response — the assays (light transmission aggregometry, impedance aggregometry), the clinical decision logic built on their results, and the pharmaceutical compositions whose efficacy those assays are used to measure. The 365 records in scope span filings from 2015 through the current data cut-off, giving a decade-plus view of how claim activity has moved between diagnostic method and drug composition.
Because publication typically lags filing by around 18 months, the most recent one to two years in any trend understate real filing activity; 2024 is treated here as the last complete year for growth comparisons.
Filing trends and technology composition
Two views of the same 365-record dataset: how filing volume has moved year over year, and how those records distribute across IPC subclasses. A record can carry more than one class, so class shares are read against the full record count, not against each other.
Filing activity, 2017–2026
Volume peaked early at 33 records in 2018, dipped, then rebuilt — 7 records in 2021 climbing to 11 in 2024, a +57% increase over that three-year window. 2025 and 2026 figures are still filling in as publications catch up to filing dates.
Technology composition by IPC subclass
Medicinal preparations (A61K) touch 67.9% of records and therapeutic activity (A61P) 41.4%, confirming this is primarily a pharmaceutical-composition field with assay method claims (G01N, 29.3%) as a substantial but secondary layer, and peptide/protein (C07K, 17.0%) and heterocyclic compound (C07D, 15.6%) chemistry filling out the rest.
Shares are the percentage of the 365 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Platelet Function and Antiplatelet Response with Eureka
This page is one run against one query. Ask Eureka your own question about platelet function and antiplatelet response and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in the dataset
Dual Anti-platelet medication/aspirin response and reactivity test using synthetic collagen (US20150226756A1)
The filing describes tests that measure functional platelet aggregation using Light Transmission Aggregometry Assays or flow cytometry with synthetic, self-assembling human type I collagen, applied to predicting and measuring an individual's sensitivity and residual platelet activity while on dual aspirin/antiplatelet therapy, plus kits for the assays.Filed by JNC Corporation, 2015-08-13.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US8835407B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using… | 124 |
| 2 | US20130095179A1 | Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy | 123 |
| 3 | US20110104146A1 | Antithrombotic agents and methods of use thereof | 70 |
| 4 | US8058023B2 | Assessment of cardiac health and thrombotic risk in a patient | 47 |
| 5 | US8680052B1 | Methods of treating, reducing the incidence of, and/or preventing ischemic events | 32 |
| 6 | US8236782B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using… | 32 |
| 7 | US20070243632A1 | Methods for measuring platelet reactivity of patients that have received drug eluting stents | 31 |
| 8 | US20060199239A1 | Assessment of cardiac health and thrombotic risk in a patient | 31 |
| 9 | US20100291056A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using… | 24 |
| 10 | US20220168353A1 | Freeze-dried platelet derivative compositions for treating antiplatelet induced coagulopathy | 22 |
Citation counts reflect influence within the searched corpus and favour older filings; they are not a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data implies for a filing decision
Three patterns stand out once the raw numbers are set against each other: where citation weight sits, where filing has concentrated, and where the technology mix suggests open ground.
Composition claims dominate the citation graph
The two most-cited records in the dataset, US8835407B2 and US20130095179A1, both sit in drug-composition and resistance-management territory rather than pure assay method. New assay-method filings entering this space inherit less prior-art density than a composition filer would face.
The leader sits well ahead of the field
With 45 records, the leading assignee holds roughly double the fifth-place count of 20, and the top ten together account for 59.5% of all 365 records. That leaves a long tail of single- and few-filing entrants below rank ten.
Assay-method claim space is comparatively open
G01N material-analysis claims appear on 107 of 365 records against 248 for A61K medicinal preparations. The gap suggests device- and protocol-level assay claims, as opposed to drug-composition claims, are less thoroughly staked out.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to platelet function and antiplatelet response, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| President and Fellows of Harvard College | Children's Medical Center Corporation | 12 |
| JNC Corporation | TROLIO WILLIAM M | 7 |
| IPCA Laboratories Limited | NELLITHANATH THANKACHEN BYJU | 3 |
| IPCA Laboratories Limited | KUMAR ASHOK | 3 |
| IPCA Laboratories Limited | SOUDAGAR SATISH RAJANIKANT | 2 |
| IPCA Laboratories Limited | SAHAL GAURAV | 2 |
| IPCA Laboratories Limited | MOJE DEVKI | 2 |
| IPCA Laboratories Limited | MATHUR ARPANA PRASHANT | 2 |
Ten co-assignee pairs appear in the dataset; the strongest links academic centres to hospital or corporate co-filers, consistent with clinical-trial-driven joint filings rather than pure corporate R&D partnerships.
Assignee landscape
The ranking covers 99 assignees counted in records — the complete set the data endpoint returns, not a top-50 or top-100 cut. Filing is concentrated at the top and thins quickly after rank ten.
A clear volume leader
The top assignee's 45 records are more than double the fifth-place count of 20, marking it as the dominant single filer in this dataset rather than one of several comparable leaders.
A fast drop-off after the top five
Record counts fall from 20 at fifth place to 12 at tenth, and the top ten combined reach 217 records, 59.5% of all 365 in scope — meaning most of the remaining 89 ranked assignees hold only a handful of filings each.
Recent-year activity has gone quiet for past leaders
Several previously active assignees, including academic and pharma filers, show zero filings in the latest tracked year, with year-on-year drops of -100% for at least two. Given the 18-month publication lag, this likely reflects incomplete recent data rather than an actual halt in R&D.
| Assignee | Recent year | YoY |
|---|---|---|
| IPCA Laboratories Limited | 0 | — |
| Chiesi Farmaceutici S.p.A. | 0 | — |
| CyDex Pharmaceuticals, Inc. | 0 | — |
| University of Vermont | 0 | -100% |
| MedImmune Ltd | 0 | — |
| Cellphire, Inc. | 0 | -100% |
| JNC Corporation | 0 | — |
| T2 Biosystems, Inc. | 0 | — |
Where to take this
The dataset points to specific next questions rather than a single conclusion. These are the follow-ups worth running before committing a filing strategy.
Map the white space claim by claim
The gap between assay-method coverage (29.3%) and composition coverage (67.9%) is a starting hypothesis, not a filed answer — it needs claim-level review against the specific sub-branch you intend to enter.
Explore white space in EurekaWatch the top assignee's next moves
A leader holding 45 of 365 records sets the terms of freedom-to-operate for anyone filing composition or resistance-management claims; tracking its recent filings is more informative than tracking the field average.
Track assignee activity in EurekaRe-run the trend once 2025 fills in
Because publication lags filing by about 18 months, the 2025-2026 dip in the trend chart is expected, not a genuine slowdown; revisit the growth comparison once those years are more complete.
Set a trend alert in EurekaCommon questions on this landscape
One assignee leads with 45 of the 365 records in scope, well ahead of the fifth-place holder at 20. The top five assignees combined account for 40.0% of all records, and the top ten reach 59.5%, so filing activity is concentrated at the top with a long tail of smaller filers below rank ten. The ranking covers 99 assignees total, the full set returned by the underlying dataset rather than a curated top-50 or top-100.
Filings ran from 16 in 2017 to a peak of 33 in 2018, then rebuilt from 7 in 2021 to 11 in 2024, a +57% increase over that three-year span. Figures for 2025 and 2026 appear lower, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop in activity. 2024 is the most recent year that can be treated as a complete data point for growth comparisons.
Medicinal preparations under IPC class A61K appear on 67.9% of the 365 records, and therapeutic-activity claims under A61P appear on 41.4%, making pharmaceutical composition the dominant claim type. Material analysis and testing methods under G01N cover 29.3% of records, a meaningfully smaller share, which points to assay-method claims being less saturated than drug-composition claims. Peptide and heterocyclic chemistry classes fill out most of the remainder.
The filing, from JNC Corporation, covers tests measuring functional platelet aggregation using Light Transmission Aggregometry Assays or flow cytometry with synthetic, self-assembling human type I collagen, applied specifically to dual aspirin/antiplatelet therapy monitoring. It blocks that specific reagent-and-method combination for dual-therapy reactivity testing, not platelet function assays generally. Work using different reagent chemistries, different collagen sources, or single-agent rather than dual-therapy monitoring sits outside its claim scope, though a full freedom-to-operate check should confirm claim boundaries in the granted or current version.
The clearest gap is between assay-method claims (29.3% of 365 records under G01N) and drug-composition claims (67.9% under A61K), suggesting device- and protocol-level assay work is comparatively under-claimed relative to pharmaceutical compositions. Sub-areas such as impedance aggregometry device design, sample-handling-window protocols, and cross-platform assay-agreement methods show lower apparent filing density than the therapy-composition core. Nanotechnology-enabled sensing (B82Y, 4.1% of records) is also a small slice worth checking claim-by-claim before assuming it is genuinely open.
Research Platelet Function and Antiplatelet Response in depth with Eureka
Go past this page: query the whole platelet function and antiplatelet response corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.